Diabetic cataract-pathogenesis, epidemiology and treatment
- PMID: 20634936
- PMCID: PMC2903955
- DOI: 10.1155/2010/608751
Diabetic cataract-pathogenesis, epidemiology and treatment
Abstract
Cataract in diabetic patients is a major cause of blindness in developed and developing countries. The pathogenesis of diabetic cataract development is still not fully understood. Recent basic research studies have emphasized the role of the polyol pathway in the initiation of the disease process. Population-based studies have greatly increased our knowledge concerning the association between diabetes and cataract formation and have defined risk factors for the development of cataract. Diabetic patients also have a higher risk of complications after phacoemulsification cataract surgery compared to nondiabetics. Aldose-reductase inhibitors and antioxidants have been proven beneficial in the prevention or treatment of this sightthreatening condition in in vitro and in vivo experimental studies. This paper provides an overview of the pathogenesis of diabetic cataract, clinical studies investigating the association between diabetes and cataract development, and current treatment of cataract in diabetics.
References
-
- Klein R, Klein BEK. Diabetic eye disease. The Lancet. 1997;350(9072):197–204. - PubMed
-
- Guillausseau P-J, Massin P, Charles M-A, et al. Glycaemic control and development of retinopathy in type 2 diabetes mellitus: a longitudinal study. Diabetic Medicine. 1998;15(2):151–155. - PubMed
-
- Turner R. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) The Lancet. 1998;352(9131):837–853. - PubMed
-
- Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44(2):156–163. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
